| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 8 Jul 2025 | 27 Jun 2025 |
| Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/07/2025 inter alia to consider and approve 1. To consider and approve Notice of 36th Annual General Meeting. 2. To consider and approve Boards Report for Financial Year 2024-2025. 3. Any other business with the permission of Chair. approved as below: 1. The date of 36th Annual General Meeting fixed as 22nd August 2025 at 11:30 a.m. (1ST) through Video Conferencing (VC) I Other Audio-Visual Means (OAVM). 2. The book closure (Register of Members and Share Transfer Books) for the purpose of 36th Annual General Meeting will commence from 16th August 2025 to 22nd August 2025 (both days inclusive). 3. The cut-off date for determining eligible shareholders for remote e-voting/ e- voting will be on 15th August 2025. Any person, who is a member of the company as on 15th August 2025, shall be entitled to vote through remote e-voting/ e- voting. The remote e-voting peri-od commences on 19th August 2025 (9:00 a.m.) and ends on 21st August 2025 (5 :00 p.m.). (As Per BSE Announcement dated on 08.07.2025) | ||
| Board Meeting | 26 May 2025 | 17 May 2025 |
| Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 26th May 2025 inter alia: 1. To consider and approve Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31st March 2025. 2. Any other business with the permission of Chair. AS per enclosed pdf. (As Per BSE Announcement dated on 26.05.2025) | ||
| Board Meeting | 4 Feb 2025 | 24 Jan 2025 |
| VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 inter alia to consider and approve Board meeting scheduled to be held on 04th February 2025 This has reference to the meeting of Board of Directors held on 4th February 2025 inter alia considered and approved: 1. Unaudited Financial Results for the quarter and nine months ended on 31st December 2024 along with Limited Review report. 2. The Board of Directors of the Company, based on a legal opinion, has resolved to write off the time-barred unsecured Foreign Currency Convertible Bond (FCCB) liability of ?38.68 crores including interest, which has remained unclaimed for over 10 years and is no longer legally enforceable under applicable laws. (As Per Bse Announcement Dated on 04.02.2025) | ||
| Board Meeting | 29 Nov 2024 | 29 Nov 2024 |
| Board approved the establishment of wholly owned subsidiary in Hungary by its wholly owned subsidiary Venus Pharma GmbH, Germany | ||
| Board Meeting | 29 Oct 2024 | 18 Oct 2024 |
| VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve Boar meeting is scheduled for 29th October 2024 to inter alia consider and approve Unaudited financial results for the period ended on 30th September 2024. Outcome of Board meeting dated 29.10.24 (As per BSE Announcement Dated on 29/10/2024) | ||
| Board Meeting | 13 Aug 2024 | 1 Aug 2024 |
| VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve 1. To consider and approve Unaudited Standalone and Consolidated Financial Results for the period ended on 30th June 2024. 2. To consider the appointment of independent director(s). 3. To finalize the date of 35th Annual General Meeting of the company. 4. Any other business with permission of the Chair. outcome as per the pdf attached. (As Per Bse Announcement Dated on 13.08.2024) | ||
The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner.
The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
